Not recruitingISRCTN75061806
Efficacy and safety of agomelatine (25-50 mg/day) for 12 weeks in patients with Generalized Anxiety Disorder
Research studyAges 18+Multiple countries
Understand this study
Who could participate?
This study is for people with anxiety. Listed age limits: from 18 years. Other eligibility criteria apply.
- Listed locations
- China · Malaysia and 3 more locations
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Not recruiting
- Enrollment listed in the registry
- Not clearly listed
- Sponsor
- Institut de Recherches Internationales Servier (France)
- Sponsor type
- Research institute
- Study type
- Other
- Intervention type
- Other / unclear
- Locations
- China, Malaysia, Singapore, ...
- Age range
- Over 18 Years
- Official registry ID
- ISRCTN75061806
- Official title
Show the full official title
Efficacy and safety of agomelatine (25-50 mg/day) for 12 weeks in patients with Generalized Anxiety Disorder
Recruitment & locations
Not recruitingThis badge reflects the study status reported by the registry. Check the registry for the latest information.
China · Malaysia · Singapore
2 more locations
- Taiwan
- Thailand
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Institut de Recherches Internationales Servier (France), a research institute.
Who can participate?
This study is for people with anxiety. Listed age limits: from 18 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as not recruiting.
